SCHEMBL2420087

SCHEMBL2420087

Cc1ccccc1CC(=O)Nc1n[nH]c2sc(C(=O)Nc3cccc(Cl)c3)cc12

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.49
TP53 P04637 3/20 0.49
KCNJ5 P48544 1/20 0.46
KCNJ3 P48549 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
POLB P06746 2/20 0.43
P2RX4 Q99571 1/20 0.42
P2RY14 Q15391 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
TTK P33981 1/20 0.41
AHR P35869 1/20 0.40
HSD17B10 Q99714 1/20 0.40
LCK P06239 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2416733 0.91 MAPT (0.47) MAPTTP53L3MBTL1MEN1KMT2A
SCHEMBL2422270 0.89 KCNJ5 (0.46) MAPTTP53KCNJ5KCNJ3L3MBTL1
SCHEMBL2414134 0.89 SMN1; SMN2 (0.45) MAPTTP53L3MBTL1MEN1KMT2A
SCHEMBL2413756 0.88 POLB (0.46) MAPTTP53MEN1KMT2APOLB
SCHEMBL2414965 0.87 LCK (0.50) MAPTMEN1KMT2APOLBTTK
SCHEMBL2418505 0.87 RXFP1 (0.52) MAPTTP53L3MBTL1MEN1KMT2A
SCHEMBL2418693 0.87 TP53 (0.45) TP53POLBRXFP1TTK
SCHEMBL2420156 0.86 MAPT (0.47) MAPTTP53L3MBTL1MEN1KMT2A
SCHEMBL2417616 0.85 KMT2A (0.43) MAPTMEN1KMT2APOLBLCK
SCHEMBL2411622 0.85 CSNK1D (0.44) MAPTTP53MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7541378-B2 Condensed heterocyclic pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2009-06-02 US claimed
EP-1530573-B1 CONDENSED HETEROCYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PFIZER ITALIA SRL (IT) 2008-03-19 EP claimed
US-8017643-B2 Condensed heterocyclic pyrazole derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-09-13 US disclosed
US-20100286223-A1 Condensed Heterocyclic Pyrazole Derivatives as Kinase Inhibitors PFIZER ITALIA S.R.L. (IT) 2010-11-11 US disclosed
US-7786048-B2 Condensed heterocyclic pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2010-08-31 US disclosed
US-20090233813-A1 Condensed Heterocyclic Pyrazole Derivatives as Kinase Inhibitors PFIZER ITALIA S.R.L. (IT) 2009-09-17 US disclosed
EP-1530573-B1 CONDENSED HETEROCYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PFIZER ITALIA SRL (IT) 2008-03-19 EP disclosed
EP-1530573-A1 CONDENSED HETEROCYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2005-05-18 EP disclosed
WO-2004013146-A1 CONDENSED HETEROCYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A (IT) 2004-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286223-A1 Condensed Heterocyclic Pyrazole Derivatives as Kinase Inhibitors CDK2, MAP3K19, MAP3K15 MAPT 2293/4885TP53 282/4885KCNJ5 911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.